| Pair Name | Demethoxycurcumin, Cisplatin | ||
| Phytochemical Name | Demethoxycurcumin (PubChem CID: 5469424 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Demethoxycurcumin, Cisplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| In Vivo Model | For a xenograft model, A549/DDP cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice. | |||
| Result | The findings from the present study suggested that DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway. Oncol Lett. 2020 Nov;20(5):209. doi: 10.3892/ol.2020.12072. | Click |
